The first thing my uncle Ray asked the urologist, before she had finished sitting down, was "is kidney cancer curable?" She did not dodge it. She said: "Yours, very probably, yes. Let me show you why." Then she turned her screen round and walked him through the scan, the size of the tumour, the fact that it had not reached the fat around the kidney or the lymph nodes, and what the numbers said for someone in exactly his position. He told me afterwards that the fifteen minutes she spent explaining the stage did more for his sleep than anything in the following six months.
Most people never get that conversation in full. They get a diagnosis, a lot of fear and a Google search that lands on a survival statistic with no context. So this article is the conversation Ray had, written down: what the kidney cancer survival rate actually means by stage, when kidney cancer is curable and when the goal changes to control, what each treatment involves, and how much the landscape has shifted for advanced disease in the last eight years. All the numbers are sourced, and where they are uncertain, I say so.
The short answer
Yes, kidney cancer is curable for most people, because most people are diagnosed while it is still confined to the kidney. About two thirds of kidney cancers are found at a localised stage, and for those the five year relative survival rate is 93 percent, with surgery alone usually the only treatment needed. For cancer that has reached nearby structures or lymph nodes it is 74 percent. For cancer that has spread to distant organs it is 17 percent in the most recent US registry data, though that figure comes from a period before modern immunotherapy combinations were standard and is rising (American Cancer Society, Survival Rates for Kidney Cancer, SEER 2013 to 2019).
Two cautions about survival statistics. They describe large groups of people diagnosed years ago, not you, and they cannot account for your age, general health, tumour grade or the treatments that have arrived since. "Relative survival" also compares people with cancer to people of the same age without it, so a 93 percent figure means five year survival is 93 percent of what it would be anyway. For a fit person with a small tumour, the realistic chance of being cured is higher than the headline number suggests.
Understanding the stage: what the letters and numbers mean
| Stage | What it means | Usual goal |
|---|---|---|
| Stage 1 | Tumour 7 cm or smaller, confined to the kidney (T1a under 4 cm, T1b 4 to 7 cm) | Cure, usually with kidney sparing surgery or, for small tumours, surveillance or ablation |
| Stage 2 | Tumour larger than 7 cm, still confined to the kidney | Cure with surgery, usually removal of the whole kidney |
| Stage 3 | Tumour has grown into major veins or fat around the kidney, or reached nearby lymph nodes | Cure attempted with surgery, often followed by a year of immunotherapy to lower recurrence risk |
| Stage 4 | Tumour has spread beyond the kidney area to distant organs (lung, bone, liver, brain) or grown into the adrenal gland and beyond | Long term control with drug treatment; cure is possible in a minority, especially with limited spread that can be removed |
Alongside stage, the pathologist's grade (1 to 4, how abnormal the cells look) and the subtype (clear cell, papillary, chromophobe and rarer types) shape the outlook. Chromophobe tumours, for example, have an excellent prognosis; some rare subtypes behave more aggressively. Ask for all three.
Small tumours: sometimes the best treatment is careful watching
If your tumour is under 4 cm, it helps to know that roughly 20 to 30 percent of masses this size turn out to be benign when removed, and that even the cancerous ones usually grow slowly. Registries following people on active surveillance show average growth of around 0.3 cm a year and spread to other organs in fewer than 2 percent over several years (Jewett et al., European Urology, 2011; Pierorazio et al., European Urology, 2015). For older people or those with other health problems, surveillance with scans every six to twelve months is a recognised standard of care, not a compromise.
A biopsy can help settle whether a small mass is cancer at all, and is used increasingly before deciding between surveillance, ablation and surgery.
Surgery: the treatment that cures most kidney cancers
Partial nephrectomy: keep as much kidney as possible
For tumours under 7 cm where it is technically feasible, guidelines from both the American Urological Association and the European Association of Urology recommend removing the tumour with a margin while leaving the rest of the kidney in place. Cancer control is equivalent to removing the whole kidney, and the long term benefit to kidney function is large: in one landmark series, 65 percent of people who lost a whole kidney developed chronic kidney disease within three years, compared with 20 percent after partial nephrectomy (Huang et al., Lancet Oncology, 2006). Most partial nephrectomies are now done robotically through small incisions, with a hospital stay of one to three nights.
Radical nephrectomy: removing the whole kidney
For larger tumours, tumours in the middle of the kidney or those growing into the renal vein, the whole kidney is removed, usually laparoscopically or robotically. People live full, normal lives with one kidney. What changes is the importance of protecting the one that remains, which is the subject of our diet and exercise guide after kidney removal.
Ablation: heat or cold instead of a scalpel
For small tumours, especially in people who are not good surgical candidates, a needle passed through the skin under CT guidance can destroy the tumour with extreme cold (cryoablation) or heat (radiofrequency or microwave ablation). Local control is around 90 percent for tumours under 3 cm, with a slightly higher chance of needing a repeat treatment than with surgery and a much quicker recovery.
Recovery, realistically
After keyhole or robotic surgery, most people are walking the same day, home within one to three days, off strong painkillers within a week and back to desk work in two to four weeks. Heavy lifting waits six weeks. Open surgery, needed for some large or complex tumours, adds a few weeks to each of those. Fatigue outlasts pain by a wide margin; Ray described the tiredness as the surprising part, and it lifted around week six.
After surgery for stage 2 and 3: preventing it coming back
Once the tumour is out, the risk of recurrence depends on stage and grade, from under 10 percent for small low grade tumours to 40 percent or more for stage 3 high grade disease. For people at higher risk, a year of the immunotherapy drug pembrolizumab after surgery cut the chance of recurrence by about a third in the KEYNOTE-564 trial (Choueiri et al., New England Journal of Medicine, 2021), and with longer follow up it became the first adjuvant treatment in kidney cancer to improve overall survival, reducing the risk of death by 38 percent (Choueiri et al., NEJM, 2024). It is now approved in the US, UK and EU for this purpose. It is not needed for stage 1 disease, and it carries a real chance of immune side effects, so it is a conversation about individual risk rather than an automatic prescription.
Follow up after surgery involves CT scans at intervals that depend on your risk group, typically every 6 to 12 months for the first few years. Most recurrences happen within three years, but late recurrence a decade or more later is a known feature of kidney cancer, which is one reason lifelong attention to the modifiable risk factors makes sense.
Stage 4 kidney cancer: from months to years
This is where the most dramatic change has happened. Kidney cancer barely responds to chemotherapy or radiotherapy, and until 2005 the only drugs were interferon and interleukin, which helped a small minority at considerable cost. Targeted drugs such as sunitinib arrived in 2006 and roughly doubled survival. Then came immunotherapy.
- Nivolumab plus ipilimumab (two immunotherapies) produced a median survival of about 47 months in intermediate and poor risk patients in the CheckMate 214 trial, and about 11 percent had a complete response, meaning no detectable cancer, many of them lasting years (Motzer et al., NEJM, 2018).
- Pembrolizumab plus axitinib (immunotherapy plus a targeted drug) improved survival over sunitinib across all risk groups in KEYNOTE-426 (Rini et al., NEJM, 2019).
- Lenvatinib plus pembrolizumab produced the longest progression free survival seen in a first line trial, nearly two years, in the CLEAR study (Motzer et al., NEJM, 2021).
- Belzutifan, a drug that blocks the HIF-2 pathway central to clear cell kidney cancer, is approved for people with von Hippel-Lindau disease and for advanced disease after immunotherapy.
Is stage 4 kidney cancer curable? For most people the honest word is "controllable", often for years, with periods off treatment. But a meaningful minority, particularly those with a complete response to immunotherapy or with a single site of spread that can be removed or treated with focused radiotherapy, do reach long term remission that looks a great deal like cure. Ten years ago that sentence could not have been written.
One more change worth knowing: removing the kidney in people who already have spread is no longer routine. The CARMENA trial showed that for intermediate and poor risk patients, starting drug treatment without surgery was at least as good (Méjean et al., NEJM, 2018). Surgery is still used selectively for people with good risk disease and limited spread.
Questions to take to your appointment
- What is the stage, the grade and the subtype, and can you show me on the scan?
- Is a partial nephrectomy possible, and if not, why not?
- Is active surveillance or ablation a reasonable option for a tumour this size?
- What is my estimated risk of recurrence, and do I qualify for adjuvant pembrolizumab?
- What will my kidney function be afterwards, and who will monitor it?
- Are there clinical trials I should consider?
- Who is my key worker or nurse specialist, and how do I reach them?
What Ray would want you to hear
He would say the fear in the first fortnight was worse than anything that came after, and that the fear shrank in direct proportion to how much he understood. He had a robotic partial nephrectomy, two nights in hospital, six weeks of feeling tired, and then his life back. He still has scans, less often now. He also lost twenty kilograms, stopped smoking and got his blood pressure down, because his surgeon told him plainly that the remaining kidney tissue and the rest of his body would thank him. If you want to know where to start on that side, our guide to kidney cancer symptoms, causes and prevention lays out the evidence, and the BMI calculator is a fair place to check where you are.
Read next
- Kidney cancer symptoms, causes and how to lower your risk
- Kidney cancer diet and exercise: foods to eat and avoid after kidney removal
- BMI calculator with Asian and Black thresholds
- Kidney stone treatment: how to pass a stone and when you need surgery
Frequently asked questions
What is the survival rate for kidney cancer?
Across all stages, five year relative survival is about 78 percent in the US. It is 93 percent when the cancer is confined to the kidney, 74 percent when it has reached nearby tissue or lymph nodes, and 17 percent when it has spread to distant organs, though that last figure predates modern immunotherapy and is improving.
Can kidney cancer be cured without removing the kidney?
Often, yes. Partial nephrectomy removes the tumour and keeps the rest of the kidney, with the same cure rate as removing the whole organ for suitable tumours. Small tumours can also be treated with cryoablation or heat ablation, or safely watched.
Does kidney cancer come back after surgery?
For small, low grade, stage 1 tumours, recurrence is under 10 percent. For stage 3 or high grade tumours it can be 40 percent or more, which is why a year of adjuvant pembrolizumab is now offered to higher risk patients. Regular scans for at least five years are standard.
Is stage 4 kidney cancer a death sentence?
No. Median survival with modern immunotherapy combinations is around four years and rising, many people live considerably longer, and around one in ten have complete responses that can last for years. Treatment is usually aimed at long term control, and for some, lasting remission.
This article is for general information and does not replace advice from your own oncology team. Survival figures describe populations, not individuals, and your team can give you a more personal picture.
